AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Chairman’s report (verbal update)
5. Minutes of previous meeting
6. Appraisal 1
   Esomeprazole (Nexium® IV) for gastric antisecretory treatment when the oral route is not possible, such as gastro-oesophageal reflux disease (GORD) in patients with erosive reflux oesophagitis and/or severe symptoms of reflux for children and adolescents aged 1-18 years of age.

7. Appraisal 2
   Adalimumab (Humira®) in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs. Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

8. Update from All Wales Prescribing Advisory Group
9. CEPP National Audit: Patient safety – lithium prescribing
10. CEPP National Audit: - Towards more appropriate management of depression in a primary care setting
11. Guidance on prescribing for erectile dysfunction
12. Date of next meeting - Wednesday, 9th May 2012 in Abergavenny